Tesamorelin is the growth hormone peptide with the strongest evidence and our default choice. It prompts your own pituitary to release GH, raising IGF-1, and it is dosed daily and titrated to your labs.
This page covers what it is, where the evidence stands, our view on using it, and how it is dosed and monitored.
Reviewed by Dr. David Oliak, board-certified surgeon
Updated August 2026
Tesamorelin is an analog of growth-hormone-releasing hormone (GHRH), the body's own signal for GH release. It is a stabilized, degradation-resistant version of that natural hormone, developed as a pharmaceutical and FDA-approved in 2010 (as Egrifta) for HIV-associated lipodystrophy.
It signals the pituitary to release your own growth hormone in its natural, pulsatile pattern, and that GH prompts the liver to produce IGF-1, which carries most of the effects people are seeking.
Because it is stabilized, it stimulates each GH pulse more forcefully than sermorelin and produces a larger IGF-1 rise. Its feedback controls remain intact, so the pattern stays physiologic; it is stronger, not less natural.
The reason to consider it is that growth hormone and IGF-1 fall with age, bringing more body fat, less muscle, slower recovery, and poorer sleep. The aim is to restore them toward an age-appropriate level, not above it.
Where the evidence stands for tesamorelin.
Tesamorelin has formal human trial data — the reason it is FDA-approved — though that data comes from its approved indication rather than from general-wellness use, which is off-label.
In our own practice, tesamorelin is the growth hormone peptide we use most. Patients most often report better sleep and improvements in body composition. They also report maintenance — sometimes growth — of muscle, including while on GLP-1 weight-loss medication.
Our verdict: tesamorelin is our default growth hormone peptide, and the reasons are its evidence and its physiology. It has the strongest clinical record of any GH peptide, and it works by amplifying your own pulsatile GH release under intact feedback — stronger, but still physiologic.
Two disciplines govern how we use it. We do not cycle it: GHRH analogs keep growth hormone under the body's own feedback, so a washout has no pharmacologic basis, and pausing can reverse the result.
And we titrate to IGF-1, not to a fixed dose — if a tier does not move the number we escalate; if IGF-1 is at the top of the age-appropriate range we hold.
In our practice, patients most often notice better sleep and body composition, and it maintains muscle even alongside GLP-1 weight-loss treatment. We use it as one targeted tool within a plan built on the evaluation, and tesamorelin alone reaches target for most patients, which is why it is usually the only GH peptide needed.
— Dr. David Oliak, board-certified physician and surgeon
Tesamorelin is dosed once daily at bedtime, on an empty stomach, to ride the body's natural nighttime GH pulse. We dose it continuously, without cycling. We start low and titrate up to an age-appropriate IGF-1, using three dose tiers.
Tesamorelin is prescribed through a monthly membership that includes medication, shipping, and follow-up visits; labs are billed separately at Quest (no lab markup). The dose is set and adjusted by your provider to your IGF-1. For current membership pricing, see the peptide pricing page.
Tesamorelin is prescribed only after a comprehensive evaluation, because dosing it safely depends on lab data. Before starting, we run a full panel including IGF-1, A1c, fasting insulin, and metabolic markers.
We recheck IGF-1 at roughly eight to twelve weeks and then quarterly, titrating to an upper age-appropriate range and never to supraphysiologic levels. Because growth-hormone secretagogues can raise blood sugar, we also monitor glucose and A1c.
With any injected peptide, the source is a safety issue, not a detail — and with a lab-titrated therapy, so is the monitoring.
We prescribe compounded, human-use tesamorelin through a licensed pharmacy, not research-only material sold online, which is labeled not for human use and produced without a regulatory framework to confirm its contents. The compounded form we prescribe is not the branded product.
Reported side effects are generally mild and can include fluid retention and joint discomfort, which we limit by titrating to a physiologic IGF-1.
Because IGF-1 is a growth signal, tesamorelin is not appropriate for people with active or recent cancer, and is used cautiously in uncontrolled diabetes and proliferative diabetic retinopathy.
It is prescribed off-label for wellness, under supervision, with informed consent. Why "research use only" peptides are a problem →
Let's begin
Tesamorelin is prescribed after a comprehensive evaluation, including IGF-1, and is dosed to your labs over time. The evaluation is what lets us fit it to you as one targeted part of a plan — start there to see whether it fits your goals. To speak with us first, call 714-671-2005.
Growth hormone peptides, explained
Tesamorelin vs. Sermorelin — the comparison
Sermorelin — the gentler, lower-cost option
Why "research use only" peptides are a problem
It is used to raise your own growth hormone and IGF-1 for wellness and body-composition goals. Its FDA-approved use is specifically for excess abdominal fat in HIV-associated lipodystrophy; other use is off-label.
We dose it daily at bedtime, starting at 0.5 mg and titrating to 1.0 or 1.5 mg based on your IGF-1. The dose is set by your provider to a lab target, not to a fixed number.
No. It is dosed daily and continuously. GHRH analogs preserve the body's own feedback, so cycling has no pharmacologic basis, and pausing can reverse results. We track IGF-1 instead.
Yes, but only for HIV-associated lipodystrophy (as Egrifta). Use for general wellness is off-label, and the compounded form is not the branded product.
Through a monthly membership, priced by dose tier (one, two, or three vials per month). That membership includes medication, shipping, and visits. Labs are billed separately at Quest. Current pricing is on our peptide pricing page. A comprehensive evaluation is required first.
